A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

September 6, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Ovarian Neoplasms
Interventions
DIAGNOSTIC_TEST

CleoDX ovarian cancer test

A diagnostic test to assist in predicting risk of malignancy prior to surgery for patients with an adnexal mass.

Trial Locations (8)

22003

RECRUITING

Virginia Women's Health Associates, Annandale

32405

RECRUITING

Emerald Coast Clinical Research, Panama City

38305

RECRUITING

The Jackson Clinic, Jackson

75067

RECRUITING

Prime Clinical Research - Lewisville, Lewisville

75149

RECRUITING

Vast Clinical Research-Holy Cross, Mesquite

77008

RECRUITING

Next Innovative Clinical Research, Houston

85224

RECRUITING

New Horizons Clinical Trials, Chandler

89106

RECRUITING

Women's Cancer Center of Nevada, Las Vegas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Lindus Health

INDUSTRY

lead

Cleo Diagnostics Ltd

INDUSTRY

NCT06566716 - A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass | Biotech Hunter | Biotech Hunter